Description |
proprotein convertase subtilisin/kexin type 5 |
renin |
Image |
No pdb structure |
|
GO Annotations |
Cellular Component |
|
|
Molecular Function |
|
|
Biological Process |
|
|
Pathways |
|
|
Drugs |
|
- Remikiren
- Minoxidil
- N,N-dimethylformamide
- 1-Hydroxy-3-Methylbutane
- 3-Phenyl-1,2-Propandiol
- 2-Methyl-3-(2-Aminothiazolo)Propanal
- Enalkiren
- 2-Cyclopropylmethylenepropanal
- 1-Methyl-2-Oxy-5,5-Dimethyl Pyrrolidine
- N-Methyl-N-(Methylbenzyl)Formamide
- 1-Hydroxy-2-Amino-3-Cyclohexylpropane
- SPP1148
- N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOTHIAZIN-4-YL]ETHYL}ACETAMIDE
- 6-ETHYL-5-[9-(3-METHOXYPROPYL)-9H-CARBAZOL-2-YL]PYRIMIDINE-2,4-DIAMINE
- N-{2-[6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2,2-DIMETHYL-3-OXO-2,3-DIHYDRO-4H-1,4-BENZOXAZIN-4-YL]ETHYL}ACETAMIDE
- (2S)-6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-2-(3,5-DIFLUOROPHENYL)-4-(3-METHOXYPROPYL)-2H-1,4-BENZOXAZIN-3(4H)-ONE
- 6-(2,4-DIAMINO-6-ETHYLPYRIMIDIN-5-YL)-4-(3-METHOXYPROPYL)-2,2-DIMETHYL-2H-1,4-BENZOXAZIN-3(4H)-ONE
- 5-{4-[(3,5-DIFLUOROBENZYL)AMINO]PHENYL}-6-ETHYLPYRIMIDINE-2,4-DIAMINE
- 6-ethyl-5-[(2S)-1-(3-methoxypropyl)-2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine
- Aliskiren
|
Diseases |
|
|
GWAS |
- Alzheimer's disease progression score ( 29860282)
- Amyotrophic lateral sclerosis (age of onset) ( 22959728)
- Ankylosing spondylitis ( 30946743)
- Body fat distribution (leg fat ratio) ( 30664634)
- Body fat distribution (trunk fat ratio) ( 30664634)
- Diverticular disease ( 30177863)
- Glucocorticoid-induced osteonecrosis ( 26265699)
- Glucose homeostasis traits ( 25524916)
- Height ( 28552196 20881960 25282103 23563607 31562340)
- Inflammatory bowel disease ( 27569725)
- Intraocular pressure ( 29785010 31959993 30054594)
- LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716)
- LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716)
- Lead levels ( 26025379)
- Male fertility ( 22633400)
- Metabolite levels (5-HIAA) ( 23319000)
- Pursuit maintenance gain ( 29064472)
- Response to fenofibrate (adiponectin levels) ( 23149075)
- Systemic sclerosis ( 30247649)
- Takayasu arteritis ( 25604533)
- Total ventricular volume (Alzheimer's disease interaction) ( 21116278)
- Vascular brain injury ( 25188341)
- Waist circumference adjusted for BMI (adjusted for smoking behaviour) ( 28443625)
- Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction) ( 28443625)
- Waist circumference adjusted for BMI in non-smokers ( 28443625)
- Waist circumference adjusted for body mass index ( 25673412)
|
- Blood protein levels ( 29875488)
- Blood protein levels in cardiovascular risk ( 28369058)
- Response to cognitive-behavioural therapy in anxiety disorder ( 31123309)
|
Interacting Genes |
19 interacting genes:
AMH
APPBP2
ATN1
CACNA1A
GLRX3
ITGA6
KRTAP10-3
KRTAP10-7
KRTAP10-8
KRTAP4-12
KRTAP5-9
LCE3C
MEOX2
NOTCH2NLA
NUFIP2
PMCH
PTPRM
REN
STK16
|
9 interacting genes:
AGT
ATP6AP2
CCDC24
CTSB
KCTD15
M6PR
PCSK1
PCSK5
RENBP
|
Entrez ID |
5125 |
5972 |
HPRD ID |
08985 |
01564 |
Ensembl ID |
ENSG00000099139
|
ENSG00000143839
|
Uniprot IDs |
Q92824
|
P00797
|
PDB IDs |
|
1BBS
1BIL
1BIM
1HRN
1RNE
2BKS
2BKT
2FS4
2G1N
2G1O
2G1R
2G1S
2G1Y
2G20
2G21
2G22
2G24
2G26
2G27
2I4Q
2IKO
2IKU
2IL2
2REN
2V0Z
2V10
2V11
2V12
2V13
2V16
2X0B
3D91
3G6Z
3G70
3G72
3GW5
3K1W
3KM4
3O9L
3OAD
3OAG
3OOT
3OQF
3OQK
3OWN
3Q3T
3Q4B
3Q5H
3SFC
3VCM
3VSW
3VSX
3VUC
3VYD
3VYE
3VYF
4AMT
4GJ5
4GJ6
4GJ7
4GJ8
4GJ9
4GJA
4GJB
4GJC
4GJD
4PYV
4Q1N
4RYC
4RYG
4RZ1
4S1G
4XX3
4XX4
5KOQ
5KOS
5KOT
5SXN
5SY2
5SY3
5SZ9
5T4S
5TMG
5TMK
5V8V
5VPM
5VRP
6I3F
|
Enriched GO Terms of Interacting Partners? |
|
|
Tagcloud ? |
|
|
Tagcloud (Difference) ? |
|
|
Tagcloud (Intersection) ? |
|